FDA Grants Orphan Drug Designation to Dauntless Pharmaceuticals' DP1038 for the Treatment of Acromegaly

SAN DIEGO, Jan. 30, 2018 -- (Healthcare Sales & Marketing Network) -- Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics announces that the U.S. Food and Drug Administration (FD... Biopharmaceuticals, FDA Dauntless Pharmaceuticals, acromegaly

Source: HSMN NewsFeed - January 30, 2018 Category: Pharmaceuticals Source Type: news